Annovis Bio, Inc. 8-K

What Happened

• Annovis Bio, Inc. announced in a Form 8-K that Chief Financial Officer Mark Guerin is no longer employed with the company effective March 23, 2026. The filing states Mr. Guerin’s departure did not arise from any disagreement with the company or its operations, policies or practices. The company anticipates that its board will appoint CEO Maria Maccecchini to serve as Acting Chief Financial Officer until a replacement is identified.

Key Details

• Departure effective date: March 23, 2026 (Mark Guerin no longer employed as CFO).
• Reason: Company states departure did not arise from any disagreement with the company’s operations, policies, or practices.
• Interim coverage: CEO Maria Maccecchini expected to be appointed Acting CFO until a replacement is found.
• Filing: Change disclosed in a Form 8-K filed March 25, 2026.

Why It Matters

• A CFO departure is a material leadership change that investors often watch because it can affect financial oversight, reporting continuity, and investor confidence.
• With the CEO taking on acting CFO duties, investors should monitor for announcements about a permanent CFO hire and any updates to financial controls or reporting responsibilities.
• This is a management succession and governance item—no financial results or other operational changes were disclosed in this filing.